Laurence C Cheung

Senior Lecturer

Curtin University

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Laurence C. Cheung is a Senior Lecturer at Curtin University in Australia. His research focuses on leukemia, with particular emphasis on therapeutic opportunities in Down syndrome-associated leukemia, osteoclast targeting for high-risk B-cell acute lymphoblastic leukemia, and the impacts of copy number alterations in cancer. He has also contributed to studies on the efficacy of various treatment options for aggressive leukemia and improvements in pediatric cancer vaccination strategies.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (19)

Benjamin Mullin

University of Western Australia

AUSTRALIA

Laurence C Cheung

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia

Polyamine depletion limits progression of acute leukaemia

Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Preclinical Assessment of Dactinomycin in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer

Murine bone-derived mesenchymal stem cells undergo molecular changes after a single passage in culture.

The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia

The Bone Marrow Microenvironment in B-Cell Development and Malignancy

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

Therapeutic Targeting of the Leukaemia Microenvironment

Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Collaborators (19)

Benjamin Mullin

Ksenia Matlawska-Wasowska

Thierry BESSON

Mark Cruickshank

Russell Pickford

Ernest Moles

Jinbo Yuan

Rozbeh Jafari

Nicholas Gottardo

Yizhou Huang

Owen Duncan

Maria Kavallaris

Tim Lammens

Richard Lock

Filip Matthijssens

Tim Pieters

Steven Goossens

Sebastien Malinge

Rishi Kotecha

Make your next move.